K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$1.07
Prev. Close
$0.90
Prev. Day's Range
$0.86 - $1.07
52W Range
$0.78 - $3.96
Trading Volume
79.56K
MC
$46.959M
P/E Ratio
--
EPS
$-0.58
Company Overview
NYSE
Rafael Holdings, Inc. owns commercial real estate assets and interests in preclinical and clinical stage pharmaceutical companies. The company is headquartered in Newark, New Jersey.
SectorREAL ESTATE
IndustryREAL ESTATE SERVICES
Headquarters520 BROAD STREET, NEWARK, NJ, UNITED STATES, 07102
RFL represents Rafael Holdings, a company focused on the development and commercialization of cancer therapies. It supports promising companies in healthcare and technology through strategic investments. Rafael Holdings holds ownership in technologies related to drug development and aims to create innovative therapies to address critical healthcare needs.
Rafael Holdings operates in the healthcare sector and is primarily classified within the biotechnology industry. This positions the company in a dynamic space involving cutting-edge research and development of advanced medical treatments targeting various critical illnesses.
Rafael Holdings derives revenue primarily from investments in biotechnology ventures and the development of pharmaceutical candidates. Its main focus is the advancement of novel cancer therapies, which, upon successful commercialization, could represent a key driver for future income streams.
Investing in Rafael Holdings carries risks tied to its focus on biotechnology, including research and development uncertainties, regulatory hurdles, and long timelines to achieve product approvals. Additionally, reliance on successful clinical trials and market acceptance contributes to potential volatility.
Rafael Holdings does not currently pay dividends. As a biotechnology investment-focused company, its financial priorities are centered on reinvesting capital into drug development and research activities rather than distributing earnings.
In the biotechnology space, Rafael Holdings competes with other companies focused on cancer treatment, including large-cap firms like Amgen and Biogen, as well as smaller specialized biotech companies targeting oncology. Each competitor differs in research focus, scale, and market presence.
Rafael Holdings offers exposure to innovative cancer therapies and biotechnology investments. Investors may be intrigued by potential growth linked to successful clinical trials and commercialization. However, it is important to weigh these opportunities against the inherent risks of investing in the biotech sector.
Investors should consider Rafael Holdings’ pipeline of drug candidates, progress in clinical trials, and cash reserves for funding operations. The valuation reflects future expectations and risks in biotechnology development, making thorough due diligence essential for informed investment decisions.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.